ProPhase Labs, Inc. Contract Liability (Deferred Revenue)
ProPhase Labs, Inc. (PRPH) had Contract Liability (Deferred Revenue) of $1.44 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-19
- 2026-06-30: Contract with Customer, Liability, Current $1.44M.
- 2026-03-31: Contract with Customer, Liability, Current $1.01M; Contract with Customer, Liability, Current as first filed $1.84M.
- 2025-12-31: Contract with Customer, Liability, Current $1.50M.
- 2025-09-30: Contract with Customer, Liability, Current $1.37M.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.44M 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $1.01M 10-Q/A · filed 2026-07-09 | $1.84M 10-Q · filed 2026-06-30 |
| 2025-12-31 | $1.50M 10-Q · filed 2026-08-19 | |
| 2025-09-30 | $1.37M 10-Q · filed 2025-11-19 | |
| 2025-06-30 | $1.42M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $1.60M 10-Q · filed 2025-05-20 | |
| 2024-12-31 | $1.70M 10-K · filed 2026-06-01 | |
| 2024-09-30 | $1.65M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $1.82M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $1.63M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $2.38M 10-K · filed 2025-04-01 | |
| 2021-06-30 | $112.00K 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $129.00K 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $169.00K 10-Q · filed 2021-11-12 | |
| 2020-09-30 | $182.00K 10-Q · filed 2020-11-19 | |
| 2020-06-30 | $135.00K 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $93.00K 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $104.00K 10-K · filed 2021-03-31 | |
| 2019-09-30 | $118.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $111.00K 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $119.00K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $206.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |